Dr. Roger R. Dmochowski is Professor at the Department of Urology at Vanderbilt University in Nashville. He is Director of the Section of Female Pelvic Medicine and program director of the Fellowship in Pelvic Medicine at Vanderbilt. He is also Clinical Assistant Professor in Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He is also Vice Chair, Section of Surgical Sciences Vanderbilt University Medical Center, Associate Director of Quality and Safety, Vanderbilt Health System, Executive Director of Risk Prevention for Vanderbilt Health System, Executive Medical Director for Patient Safety and Quality (Surgery),Associate Chief of Staff, and Medical Director of Risk Management at Vanderbilt University Hospital. Dr. Dmochowski received his medical degree from the University of Texas Medical Branch at Galveston. He completed an internship and residency in surgery and urology at the University of Texas Medical School at Houston and at the M.D. Anderson Hospital and Tumor Institute in Texas. In addition, Dr. Dmochowski is subspecialty fellowship trained in female urology, neurourology, urodynamics and reconstructive urology. He is board certified in urology and female pelvic medicine and reconstruction. He received a Masters in Medical Management from Owen School of Business at Vanderbilt in 2014. Dr. Dmochowski has published more than 300 articles and 100 book chapters, and 440 abstracts, and has given over 260 presentations at various national and international meetings. Dr. Dmochowski is on the editorial board for the World Journal of Urology, and he is a reviewer for the Journal of Urology, and Urology. He is the Editor in Chief of Neurourology and Urodynamics. He is a Fellow of the American College of Surgeons and a member of the American Urological Association and International Continence Society. He is a trustee of the American Board of Urology. Dr. Dmochowski has been granted the Zimskind and Lifetime Achievement Awards from the Urodynamics Society for his accomplishment in clinical treatment for incontinence. His current research interests are outcomes of incontinence therapies with a particular emphasis on quality of life issues patient literacy and informed consent related to pelvic floor interventions. He also is active in bio materials evaluation.

TBD

TBD

Professor Mundy is Professor of Urology/Medical Director/consultant urological surgeon at University College London Hospitals NHS Foundation Trust. He trained in surgery/urology at Guy’s Hospital, London and became a consultant urologist in 1981. He was made Professor of Urology in 1989 and moved to the Institute of Urology/UCLH in 1995. His main surgical practice is reconstructive urology, principally for the management of urethral stricture disease, iatrogenic trauma and complex urinary incontinence. Other than complex urethral surgery he deals with the posterior urethral complications of the treatment of prostate/other pelvic cancers. He has given a number of prestigious orations; has been a visiting professor 61 times; has written 205 original publications in peer-reviewed journals, 65 chapters and 15 books; has given 806 presentations to learned societies; and travels abroad widely to operate – 158 occasions in the last 20 years. He is or has been a member or honorary member of a number of national and international societies and committees.

Dr. Spitz completed a Bachelors of Arts in Government at Cornell University. He earned his medial degree from Weil/Cornell Medical College and he completed his Urology residency at the University of Southern California, and then obtained fellowship training in infertility at the Baylor College of Medicine. Dr. Spitz has expertise in the treatment of male infertility and sexual dysfunction, and he has participated in clinical trials and research in the area of andrology, male sexual dysfunction, and male infertility. Dr. Aaron Spitz serves as a voluntary assistant clinical professor in the U.C. Irvine department of Urology, Dr. Spitz currently directs the Center for Male Reproductive Medicine and Surgery at Orange County Urology in Laguna Hills and Mission Viejo, California. Dr Spitz is the immediate past president of the California Urologic Association. He is the Orange County District representative to the Western Section of the American Urologic Association. He served as the lead delegate to the American Medial Association House of Delegates representing the American Urologic Association. He sits on the Health Policy Council of the American Urologic Association. He is co-chair of the Telehealth Task Force of the American Urologic Associsation and he serves on the AUA Workforce Work Group and the AUA Advanced Practice Practitioner Work Group as well as the AUA opioid position statement workgroup. Dr. Spitz has served as faculty for the American Urological Association's national microsurgical course. Dr. Spitz has been awarded several prestigious honors including Alpha Omega Alpha at the University of Southern California. Dr. Spitz is the author of The Penis Book: A Doctor’s Complete Guide to the Penis, from size to function and everything in between published by Rodale/Crown/Penguin which has been translated in 4 languages including Italian, Dutch, and soon to be relaasedi in Chines with rights secured in Check, Romanian, and Turkish. He appears regularly on CBS The Doctors to discuss urology topics. He is a regular guest on Sirius XM radio medical talk shows. He has authored and co-authored book chapters and articles in peer reviewed publications on the topic of telemedicine, male infertility and sexual dysfunction, including the AUA white papers on Telemedicine and on Advanced Practice Providers. . Dr Spitz is a member of the American Urological Association, American Medical Associatio, Society for the Study of Male Reproduction, American Society or Reproductive Medicine, Western Urologic Fourm, Califnoria Urology Association, California Medical Association and the American Telemedical Association. He serves as a reviewer for the Journal of Endourology and the Journal of Andrology and Urology Practice

TBD

TBD

Dr. Frimberger is board certified by the American Board of Urology. He is a Professor in the Department of Urology at the University of Oklahoma Health Sciences Center and the Chief of Pediatric Urology at the Children’s Hospital of Oklahoma. Dr. Frimberger received his medical degree from the University of Wurzburg in Germany, and completed his urology residency in a combined program through the Department of Urology of the Ludwig- Maximilians University in Munich, Germany and the Brady Urological Institute at the Johns Hopkins Hospital in Baltimore. He went on to complete a fellowship in Pediatric Urology at the Johns Hopkins Hospital and afterwards came to Oklahoma where he has been practicing for the last 15 years. Dr. Frimberger serves on the Board of the American Academy of Pediatric Urology and is a member of several national and international Societies for Pediatric Urology. Dr. Frimberger has a general pediatric urology practice and specializes in neonates and children with severe congenital urologic birth defects such as hypospadias, bladder reflux (VUR), hydronephrosis, spina bifida, DSD, bladder exstrophy and cloacal anomalies. He established the first program for robotic surgery in Pediatric Urology here in Oklahoma and is a skilled reconstructive and minimal invasive surgeon. In addition Dr. Frimberger has a number of research interests in specialized areas of pediatric urology including spina bifida and reconstructive surgery and has over 100 published articles in peer reviewed journals and contributed book chapters to a large variety of highly regarded urological and surgical text books. Dr. Frimberger is very engaged in the community and is a Board member of the Oklahoma Adaptive Sports Association (OKASA), a non-profit organization to develop, sponsor and promote recreational and competitive athletic opportunities for individuals with physical challenges. On a personal note, he is happily married to his wife for over twenty-five years, has two children and 4 dogs. As a family they enjoy outdoor activities and raise cattle and sheep.

David Miller currently serves as Chief Clinical Officer for the University of Michigan Hospital and Frankel Cardiovascular Center. Working in partnership with the UH/CVC Executive Director and Chief Nursing Officer, Dr. Miller provides oversight and direction to ensure quality and safety in clinical programs and patient care, improve patient experience, enhance staff engagement, and optimize capacity management within the two hospitals. Dr. Miller is a Professor in the Department of Urology and maintains an active role in providing direct patient care. His clinical practice focuses on the diagnosis and management of patients with prostate and kidney cancer. In addition to his clinical practice, Dr. Miller serves as Director of the Michigan Urological Surgery Improvement Collaborative (MUSIC). Funded by Blue Cross Blue Shield of Michigan (BCBSM), MUSIC is a consortium of more than 40 urology practices aiming to improve the quality and cost‐efficiency of prostate cancer care in the state of Michigan. Dr. Miller also has a broad background in health services research, including substantial experience using claims data and formal training in the advanced statistical methods used in observational data analyses. With longitudinal funding from the Agency for Healthcare Research & Quality and the National Cancer Institute, Dr. Miller's empirical research agenda focuses on comparative effectiveness research, physician‐led collaborative quality improvement, and understanding the relationship between physician organizations, integrated delivery systems, and the quality and cost of specialty care.

TBD

Dr. Goldenberg (CM, OBC, MD, FRCSC, FACS, FCAHS) is a urologic surgeon and clinical scientist with an international reputation for excellence in prostate cancer research and treatment. His current research involves the evaluation of the role of multiparametric MRI in prostate cancer, the potential use of focal therapy, patient education, daVinci robotic prostatectomy and novel treatments for benign prostatic hyperplasia. He has been recognized for his contributions to health care by being inducted into the Order of British Columbia and the Order of Canada.

Dr. Sia Daneshmand is currently an Associate Professor of Urology with Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director. His main interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer. He is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the editorial board of the Journal of Urology, Bladder Cancer Journal, Current Opinions in Urology, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) as well as the AUA/SUO Guideline Committee on testicular cancer as well as non-muscle invasive bladder cancer. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 11 consecutive years. He is an active member of the Society of Urologic Oncology, has presented over 400 abstracts at scientific meetings and has authored over 275 peer-reviewed articles, reviews, and book chapters.

Dr Olivier TRAXER is Professor of Urology : University of Paris 6th (Pierre et Marie Curie) and works in Tenon Hospital. He did a research-fellowship at Southwestern Medical School, University of Texas, Dallas-USA (Charles Y.C PAK & Margaret Sue PEARLE) to sub-specialize in Endourology and kidney stone management. As endo-urologist, his main goal is to improve the knowledge on urinary stone disease and endourology. PrTraxer Olivier is responsible in Tenon Hospital (University Pierre et Marie Curie Paris-6) of the minimally invasive surgery section and published more than 250 peer-reviewed papers. Pr Traxer is a board member of the EndoUrological Society, the French Association of Urology (AFU) and EAU board member of the EULIS, ESUT and ESU office. He is also the treasurer of SIU. He received in 2010 (Chicago-WCE) the Arthur Smith Award.

TBD

Dr. Naeem Bhojani was born and raised in Montreal, Quebec. He obtained a Bachelor of Science in Microbiology and Immunology and another in Physiotherapy from McGill University in 2001 and then completed medical school at the University of Montreal in 2006. He stayed on to do his residency at the University of Montreal finishing in 2011 before moving to Indianapolis, Indiana to spend 2 years with Dr. Lingeman at Indiana University completing his Fellowship in BPH and Stone Disease. Dr. Bhojani was recruited by The University of Montreal in 2013 to build and develop Comprehensive Kidney Stone and BPH Programs. At the University of Montreal, he has the rank of Associate Professor, Pedagogic Leader and clinical rechercher. Dr. Bhojani has published extensively in stone disease and new BPH technologies. Clinically, Dr. Bhojani is currently working on optimizing kidney stone prevention, perfecting ultrasound guided PCNL access as well as exploring new BPH technologies.

Dr. Chew is a urologist and the Director of Clinical Research at the Stone Centre at Vancouver General Hospital and an Associate Professor of Urology at the University of British Columbia in Vancouver, Canada. He is also the Chair of Research for the Endourological Society (www.endourology.org ). His main interests lie in the treatment and research of the pathophysiology of kidney stone disease. His research focus includes metabolic stone disease as well as biomaterials used in the urinary tract for ureteral stents. He has worked on various stent designs, stent coatings and drug-eluting ureteral stents to try and improve the quality of life for patients with kidney stone disease. He continues work on a degradable ureteral stent and has completed the first-in-human trials. Current studies include attempting to understand second messenger systems that are activated within the kidney and ureter once a ureteral stent has been placed. These could be exploited as future therapeutic targets for new drug eluting ureteral stents or designs to reduce symptoms. He has authored over 90 peer-reviewed manuscripts and book chapters. He is a member of the Endourologic Disease Group for Excellence (EDGE) research consortium (www.endoedge.net) and the Wisconsin Quality of Life (WISQoL) research consortium.

Dr. Pinto is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Md. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Dr. Pinto is a Board Certified Urologic Surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.

TBD

Dr. So’s current research focuses on the study of development of novel therapeutics for bladder cancer and determination of the functional role of GLI1/2 in the progression of prostate cancer to its lethal stage of androgen independence. He has characterized the functional role of different survival genes (including clusterin and Hsp27) in different tumor models (prostate, breast, lung, and bladder) in cancer progression. His current research focuses on discovery and development of novel agents to treat bladder cancer as well as development of the mechanisms of treatment resistance in renal cell carcinoma.